

**Supplementary: Discussion**



Dr. Hon Chi Suen (Hong Kong, China): Dr. Wang and colleagues reported a rare lung tumor hepatoid adenocarcinoma and reviewed the literature on this unusual pathology. Could you tell us if there are any features before surgery that may lead the physician to suspect this rare disease?



Dr. Fudong Wang (Wuxi, Jiangsu, China): HAL usually occurs at the older age male with history of smoking and most of the patients with elevated serum AFP levels. Therefore, for elderly patients with isolated lung occupation and elevated serum AFP levels, the possibility of HAL should be highly guarded after liver occupation is excluded.

**Dr. Suen: Are there any molecular studies that can help find good targeted therapy for this tumor that has poor prognosis?**

**Dr. Wang:** Molecular targeted therapy has been shown to have some curative effect. Khozin *et al.* reported the first case of treatment of HAL with the tyrosine kinase inhibitor crizotinib, resulting in a reduction in tumor volume. Gavranic *et al.* recently reported the use of platinum combined with sorafenib in the treatment of a patient with stage IV HAL and achieved partial remission with stability lasting for 11 months. Basse *et al.* reported that immunotherapy was used for HAL, the patient did have a partial response to immunotherapy. We believe that with the deepening of molecular mechanism research, the therapeutic targets of HAL will increase and eventually improve the prognosis of patients.